Self-limited acute hepatotoxicity caused by pegvisomant.
We present a case of acute severe hepatitis in a patient with acromegaly receiving combination therapy with somatostatin analogs and pegvisomant. Hepatitis resolved completely 18 weeks after diagnosis of hypertransaminasemia without discontinuation of therapy and with a close clinical and biochemical follow-up. In this case, despite the severity of the hepatitis, therapy could be continued as hypertransaminasemia was gradually decreasing after the maximum peak. We also review the literature on toxic hepatitis associated to pegvisomant therapy analyzing the etiology, clinical predisposing factors and natural evolution.
Soto Moreno
A
A
Department of Endocrinology and Nutrition, Instituto de Biomedicina de Sevilla (IBIS), Virgen del Rocio University Hospital, Seville, Spain. alfonsom.soto.sspa@juntadeandalucia.es
Guerrero Vázquez
R
R
Venegas Moreno
E
E
Palma Milla
S
S
Castaño
J P
JP
Leal Cerro
A
A
D000208:Acute Disease; D000236:Adenoma / Q000188:drug therapy; D000328:Adult; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis*; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000188:drug therapy; D019382:Human Growth Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D012075:Remission, Spontaneous
D019382:Human Growth Hormone; C406545:pegvisomant